Nimodipine
Treatment for Subarachnoid Hemorrhage
Typical Dosage: 60 mg orally every 4 hours for 21 days
Effectiveness
75%
Safety Score
68%
Clinical Trials
17
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
60 mg orally every 4 hours for 21 days
Time to Effect
Hours to days
Treatment Duration
21 days
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$100
Side Effect Mgmt:$200
Total Annual:$1,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$4,400
Nimodipine Outcomes
for Subarachnoid Hemorrhage
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+25%
Common Side Effects
Hypotension
+10%
Bradycardia
+3%
Headache
+7%
Nausea
+7%
Liver enzyme elevation
+3%
Active Clinical Trials
4 active trials recruiting for Nimodipine in Subarachnoid Hemorrhage
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
NCT05995405ACTIVE NOT RECRUITINGPHASE3
100 participants
INTERVENTIONAL
Birmingham, United States +21 more
Started: Oct 20, 2023
Nimodipine Variability in SAH
NCT07065903RECRUITING
500 participants
OBSERVATIONAL
Edmonton, Canada
Started: May 13, 2024
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
NCT07144956NOT YET RECRUITINGPHASE3
630 participants
INTERVENTIONAL
Started: Dec 15, 2025
Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
NCT07305922RECRUITING
200 participants
OBSERVATIONAL
Stockholm, Sweden
Started: Dec 1, 2025
Completed Clinical Trials
7 completed trials for Nimodipine in Subarachnoid Hemorrhage
Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases
NCT02991157COMPLETED
25 participants
OBSERVATIONAL
Bengaluru, India
Started: Dec 1, 2016
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
NCT05418348COMPLETEDPHASE1
58 participants
INTERVENTIONAL
Montreal, Canada
Started: Aug 26, 2021
Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy
NCT04309708COMPLETEDNA
300 participants
INTERVENTIONAL
Beijing, China +4 more
Started: May 1, 2018
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
NCT01893190COMPLETEDPHASE1, PHASE2
73 participants
INTERVENTIONAL
Phoenix, United States +22 more
Started: Sep 1, 2013
Stellate Ganglion Block as Adjuvant Therapy to ca Channel Blocker
NCT04100824COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Asyut, Egypt
Started: Jan 11, 2020
Management of Cerebral Vascular Spasm in Posttraumatic Subarachnoid Hemorrhage Using Combination Therapy
NCT05131867COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Zagazig, Egypt +1 more
Started: Nov 24, 2021
A Study Comparing Modified Lund Concept and Cerebral Perfusion Pressure-targeted Therapy in Secondary Brain Ischaemia.
NCT01206283COMPLETEDNA
60 participants
INTERVENTIONAL
Sarajevo, Bosnia and Herzegovina
Started: Jan 1, 2006